ArticleACS infectious diseases2016
Mycobacterial Protein Tyrosine Phosphatases A and B Inhibitors Augment the Bactericidal Activity of the Standard Anti-tuberculosis Regimen.
Article in ACS infectious diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 40 citations in OpenAlex.
- Identification of novel pyrazolo[4,3-c]pyridine and diazepane derivatives as potent inhibitors ofInfection and immunity · 2026Article
- Secreted proteins ofFrontiers in tuberculosis · 2026Review
- Article
- Discovery and Evaluation of Active Site-Directed, Potent, and Selective Sulfophenyl Acetic Amide-Based Inhibitors for the Laforin Phosphatase.Journal of medicinal chemistry · 2025Article
- Combating Tuberculosis via Restoring the Host Immune Capacity by TargetingInternational journal of molecular sciences · 2024Review
- MptpB Inhibitor Improves the Action of Antibiotics againstACS infectious diseases · 2024Article
- Shikonin and Juglone InhibitBiotech (Basel (Switzerland)) · 2023Article
- Polyphosphate kinase 1 is involved in formation, the morphology and ultramicrostructure of biofilm ofHeliyon · 2023Article
- Different modalities of host cell death and their impact onAmerican journal of physiology. Cell physiology · 2022Review
- Advances in Key Drug Target Identification and New Drug Development for Tuberculosis.BioMed research international · 2022Review
- Discovery of uncompetitive inhibitors of SapM that compromise intracellular survival of Mycobacterium tuberculosis.Scientific reports · 2021Article
- From infection niche to therapeutic target: the intracellular lifestyle ofMicrobiology (Reading, England) · 2021Review
- One Size Fits All? Not inFrontiers in cellular and infection microbiology · 2021Review
- Therapeutic Targeting of Protein Tyrosine Phosphatases fromMicroorganisms · 2020Review
- Highly Potent and SelectiveJournal of medicinal chemistry · 2020Article
- Structure-Based Design of MptpB Inhibitors That Reduce Multidrug-Resistant Mycobacterium tuberculosis Survival and Infection Burden in Vivo.Journal of medicinal chemistry · 2018Article
- Decavanadate Inhibits Mycobacterial Growth More Potently Than Other Oxovanadates.Frontiers in chemistry · 2018Article
- Glutathione-Responsive Selenosulfide Prodrugs as a Platform Strategy for Potent and Selective Mechanism-Based Inhibition of Protein Tyrosine Phosphatases.ACS central science · 2017Article
- Targeting Tyrosine Phosphatases: Time to End the Stigma.Trends in pharmacological sciences · 2017Review
- Drugging the Undruggable: Therapeutic Potential of Targeting Protein Tyrosine Phosphatases.Accounts of chemical research · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
Abstract
Novel drugs are required to shorten the duration of treatment for tuberculosis (TB) and to combat the emergence of drug resistance. One approach has been to identify and target
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.